Innovation Pharmaceuticals Inc (IPIX)

[Patientspeople]

More Facts not hype that support investments in IPIX: Kevetrin, Brilacidin AND Prurisol are all currently being evaluated in Phase 2 Trials in multiple high unmet need disease states. Each with Blockbuster potential!

Let's look at just the Prurisol Psoriasis market potential!!!

The Prurisol Phase 2b trial has a planned completion with clinical updates in 2H 2017.

About psoriasis:

Psoriasis is a common, non-contagious, auto-immune disease that affects more than 125 million people worldwide!!! Plaque psoriasis is the most common form of the disease and appears as raised, red patches covered with a silvery white buildup of dead skin cells. Scalp psoriasis is a form of psoriasis that is reported to affect approximately half of all patients with psoriasis5. The disease has a significant impact on patients' quality of life, which is an aspect of the disease underestimated by most physicians3.

Psoriasis is not simply a cosmetic problem, but a persistent, chronic (long-lasting), and sometimes distressing disease, which can affect even the smallest aspects of people’s lives on a daily basis. Up to 30% of patients with psoriasis have, or will develop, PsA8. PsA is a condition in which the joints are also affected, causing debilitating symptoms including pain, stiffness and irreversible joint damage8,9. Psoriasis is also associated with other serious health conditions, such as diabetes, heart disease and depression8.

I